≥99%
CJC-1295 with DAC + Ipamorelin Blend
A lyophilized blend pairing CJC-1295 with DAC (extended-half-life GHRH analog) and Ipamorelin (selective GHS-R1a agonist) for in-vitro receptor co-activation studies.
1 vial × $130 each
Add 3+ to unlock
volume pricing
Pay with Visa, Mastercard, or AMEX · ACH bank transfer saves 5%
Free US shipping on orders over $200, with tracking provided.
Third-party tested
Characteristics
| Property | Value |
|---|---|
| Components | CJC-1295 with DAC (D-Ala²-modified GHRH 1-29 + DAC linker) + Ipamorelin |
| CJC-1295 (with DAC) Molecular Formula | C₁₆₅H₂₆₉N₅₀O₄₆ |
| Ipamorelin Molecular Formula | C₃₈H₄₉N₉O₅ |
| CJC-1295 (with DAC) Molar Mass | 3647.27 g/mol |
| Ipamorelin Molar Mass | 711.85 g/mol |
| Physical Form | Lyophilized powder blend |
| Solubility | Both components soluble in aqueous laboratory solvent |
| Organoleptic Profile | White to off-white lyophilized powder; odorless |
| Storage Conditions | Store lyophilized at -20°C; reconstituted solution stable at 2-8°C for up to 21 days |
| Composition | Lyophilized blend of CJC-1295 with DAC acetate and Ipamorelin acetate |
How is CJC-1295 with DAC + Ipamorelin Blend Used in Research?
The CJC-1295 with DAC + Ipamorelin blend is a lyophilized research formulation combining a 30-amino acid GHRH analog with a Drug Affinity Complex (DAC) maleimide modification (3647.27 g/mol) and a 5-amino acid synthetic pentapeptide (711.85 g/mol) for in-vitro two-receptor co-activation studies. Distinct from the CJC-1295 no DAC variant of this blend in pharmacokinetic profile: the DAC modification covalently couples to endogenous albumin in preclinical models, extending serum half-life from minutes (no DAC) to days. Supplied as a laboratory research standard targeting GHRH-R and GHS-R1a binding assays in parallel. Not for use in any living organism.
Characterization workflows profile the blend in recombinant GHRH-R and GHS-R1a expression systems with standard biochemical readouts including cAMP accumulation (Gs-cAMP-PKA pathway) and IP1/calcium-flux panels (Gq/11-PLC-calcium pathway). The DAC component lets researchers model sustained-baseline GHRH-R activation, while Ipamorelin's pulsatile GHS-R1a activation is profiled against that baseline — a common research framing for studying convergent signaling under steady-state versus pulsed-stimulus conditions.
Researchers use this blend as a combined reference mixture for analytical method development (HPLC/LC-MS comparability assays requiring simultaneous quantitation of both peptides) and as a two-receptor co-activation reference for functional characterization of novel GHRH analogs and GHS-R1a agonists. The DAC variant is the appropriate reference for studies modeling extended-pulse-frequency GH-axis dynamics; the no-DAC variant remains the appropriate reference for short-half-life pulse-burst protocols.
This product is supplied in a lyophilized form and requires reconstitution prior to laboratory handling. For research and laboratory use only. Not for human or veterinary consumption.
Areas of Study
Sustained-Baseline + Pulsed-Stimulus Studies
DAC-extended GHRH-R activation provides a steady-state baseline against which Ipamorelin's pulsatile GHS-R1a stimulus can be profiled in two-receptor functional assays.
Two-Receptor In-Vitro Co-Activation
Applied as a combined reference mixture for parallel GHRH-R and GHS-R1a binding and functional readouts in recombinant cell systems.
Pharmacokinetic Method Development
Used as the long-half-life reference standard for HPLC and LC-MS workflows quantifying albumin-bound versus free GHRH-analog fractions in preclinical samples.
Receptor Selectivity Profiling
Applied in multi-receptor competitive-binding panels to profile each component's selectivity signature within the two-component blend.
Convergent Signaling Characterization
Profiles Gs-cAMP-PKA versus Gq/11-PLC-calcium pathway readouts simultaneously in cultured somatotroph cell lines.
References
- [1]Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
- [2]Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
- [3]Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
- [4]Bowers CY, Granda R, Mohan S, et al. (2004). Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I) by a combination of the GH-releasing peptide-6 and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 89(10), 5174-5181.
- [5]Léger J, Reverchon M, Porquet D, et al. (2009). Long-acting CJC-1295 analog stimulates the GH-IGF-I axis in healthy and growth-deficient preclinical models. Growth Hormone & IGF Research, 19(2), 137-144.
Disclaimer: The information provided is for research reference only and does not constitute medical advice. Products are sold strictly for in-vitro research use.
Certificate of Analysis (COA)
Third-Party Verified Quality
Every batch of CJC-1295 with DAC + Ipamorelin Blendis independently tested by an A2LA-accredited (ISO 17025:2017) third-party laboratory using HPLC-UV/VIS for purity and measured quantity. Each COA carries the lab's signed report and a batch-specific lot number. We publish these results publicly so you can verify exactly what you're getting.
View Lab ResultsRelated Research
Preclinical research summaries from our research blog covering the mechanisms and pharmacology relevant to this compound.
The Synergistic Amplification of GH Pulses: Combining GHRH and GHRP Pathways
9 minblog.stillwaterbiolabs.com
Ipamorelin Selectivity: Why Ghrelin Receptor Specificity Matters in Research
8 minblog.stillwaterbiolabs.com
GHRH Analogs vs GH Secretagogues: Distinct Mechanisms of GH Axis Stimulation
9 minblog.stillwaterbiolabs.com
Related Products
GIP3
10mg – 30mg
Triple-agonist research peptide targeting GIP, GLP-1, and glucagon receptors in preclinical metabolic studies.
CJC-1295 (no DAC)
5mg – 10mg
CJC-1295 is a 30-amino acid synthetic GHRH analog with a Drug Affinity Complex modification, supplied for in-vitro receptor-binding and half-life characterization studies.
Ipamorelin
5mg – 10mg
Ipamorelin is a 5-amino acid synthetic peptide growth hormone secretagogue supplied for in-vitro GHS-R1a receptor-binding assays and selectivity profiling.
Tesamorelin
5mg – 10mg
A synthetic GHRH analog studied in preclinical models for growth hormone pathway stimulation and preclinical metabolic-parameter studies in rodent models.
Frequently Bought Together
CJC-1295 with DAC + Ipamorelin Blend
10mg (5mg/5mg)
$130
GIP3
10mg
$100
CJC-1295 (no DAC)
5mg
$45
Bundle total
$275